DEXCOEUR: Evaluation of the Hemodynamic Effect of Dexmedetomidine in Scheduled Outpatient Surgery
Study Details
Study Description
Brief Summary
Ambulatory surgery is increasingly used in anesthesia. In case of general anesthesia, it is recommended to use anesthesia molecules with a short half-life and low doses of opiates to ensure a rapid awakening and to prevent nausea and vomiting by systematic administration of anti-emetics during the operation.
Opiates (including sufentanil) have recently been called into question because of the nausea and vomiting and the delay in waking up induced by these molecules. To combat these side effects, the authors have proposed either to reduce the doses or to substitute them with dexmedetomidine, a sedative antihypertensive drug. Recent studies have demonstrated that opiates used in general anesthesia can be replaced by dexmedetomidine. However, literature data are controversial concerning the hemodynamic impact. No study has compared the hemodynamic profile of opioid-free anesthesia with dexmedetomidine versus conventional anesthesia with opioids.
The ambulatory context lends itself to the use of dexmedetomidine because it is aimed at a population without strong cardiac pathology, concerns non-major interventions, with the need to optimize pain and side effects.
The study authors therefore wish to compare the effects of induction of general anesthesia with low-dose Dexmedetomidine versus sufentanil, on post-induction hemodynamic stability in scheduled outpatient surgeries. The investigators hypothesize that hemodynamic stability at induction of general anesthesia with low-dose dexmedetomidine is not inferior to that obtained with sufentanil in scheduled ambulatory surgeries.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Dexmedetomidine
|
Drug: Dexmedetomidine
Induction of general anesthesia by administration of dexmedetomidine 0.5µg/Kg (maximum dose 50 µg) in titration by bolus of 10µg intravenously over 5 minutes
|
| Active Comparator: Sufentanil
|
Drug: Sufentanil
Induction of general anesthesia by administration of sufentanil 0.25µg/Kg (maximum dose 20 µg) intravenously at anesthetic induction.
|
Outcome Measures
Primary Outcome Measures
- Intraoperative hemodynamic stability during anesthesia between groups [Within 60 minutes after induction]
Incidence of mean arterial pressure < 60 mmHg
Secondary Outcome Measures
- Intraoperative hemodynamic stability according to baseline mean arterial pressure between groups [Within 60 minutes after induction]
Percentage of patients with 30% decrease in mean arterial pressure from baseline
- Intraoperative heart rate between groups [Within 60 minutes after induction]
Percentage of patients with bradycardia ≤45bpm/min
- Intraoperative hypertensive episodes between groups [Within 60 minutes after induction]
Percentage of patients with at least one episode of arterial hypertension (mean arterial pressure > 100mmHg)
- Hemodynamic stability in the ICU between groups [Day 0 at discharge from ICU]
Percentage of patients with at least one episode of a Systolic Blood Pressure below 90mmHg (SBP < 90mmHg) in the ICU
- Intraoperative vasopressor use between groups [Day 0, during surgery]
Amount of IV Ephedrine (in mg) administered intraoperatively to maintain mean arterial pressure > 60 mmHg
- Intraoperative IV Atropine use between groups [Day 0, during surgery]
Amount of IV Atropine (in µg) administered intraoperatively to maintain a heart rage > 45bpm
- Failure of ambulatory management between groups between groups [Day 1]
Percentage of patients hospitalized after surgery
- Patient reported pain between groups [Day 0]
Pain reported on a 0-10 visual analog scale
- Patient reported pain between groups [Day 1]
Pain reported on a 0-10 visual analog scale
- Patient reported pain between groups [Day 2]
Pain reported on a 0-10 visual analog scale
- Patient reported pain between groups [Day 7]
Pain reported on a 0-10 visual analog scale
- Immediate nausea and vomiting between groups [Day 0 during ICU stay]
Percentage of patients with nausea and vomiting according to use of Ondansetron IV
- Post-operative nausea and vomiting between groups [Day 0 at discharge from surgery]
Percentage of patients reporting absence/presence nausea and vomiting
- Post-operative nausea and vomiting between groups [Day 1]
Percentage of patients reporting absence/presence nausea and vomiting
- Post-operative nausea and vomiting between groups [Day 2]
Percentage of patients reporting absence/presence nausea and vomiting
- Post-operative nausea and vomiting between groups [Day 7]
Percentage of patients reporting absence/presence nausea and vomiting
- Patient postoperative recovery between groups [Day 2]
Quality of Recovery questionnaire (QoR-40) (score 0-200)
- Patient satisfaction with perioperative management between groups [Day 2]
Evaluation of Experience of General Anesthesia questionnaire (EVAN-G) (score 5-100)
- Occurrence of adverse events after surgery between groups [Day 2]
Absence/presence of the following adverse events: bleeding, hematoma or re-hospitalization
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient with scheduled surgery under general anesthesia for one of the following: oral, orthopedic, urological, digestive and gynecological surgeries.
-
The patient must have given their free and informed consent and signed the consent form
-
The patient must be a member or beneficiary of a health insurance plan
Exclusion Criteria:
-
The subject is in a period of exclusion determined by a previous study
-
The subject is unable to give consent
-
It is impossible to give the subject informed information
-
The patient is under safeguard of justice or state guardianship
-
Patient with a known allergy to dexmedetomidine or other drugs.
-
Patient with a contraindication to general anesthesia or outpatient management.
-
Patient treated with beta-blocker, ACE inhibitor or ARB2
-
Patient with an ASA4 score.
-
Patient with HR < 50 bpm.
-
Patient with the following cardiovascular comorbidities: coronary insufficiency, obstructive cardiomyopathy, severe hypertension, ventricular rhythm or conduction disorder.
-
Patient with hepatic (prothrombin rate < 70%, liver enzyme/Bilirubin X 3) and/or renal (clearance < 50 ml.min) insufficiency.
-
Pregnant, parturient or nursing patient
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHU de Nîmes | Nîmes | France |
Sponsors and Collaborators
- Centre Hospitalier Universitaire de Nīmes
Investigators
- Principal Investigator: Yann Gricourt, CHU de Nimes
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NIMAO/2022-1/YG01